original ) (raw )Pharmacotherapy to reduce arrhythmic mortality
Amit Vora
Indian Heart Journal, 2014
View PDFchevron_right
Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative
Jean-pierre Valentin , Hugo Vargas
American Heart Journal, 2009
View PDFchevron_right
NHLBI Working Group: Translation of Therapies for Protecting the Heart from
David A Lathrop
View PDFchevron_right
Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Socie...
Stefan Agewall
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2018
View PDFchevron_right
New drugs vs. old concepts: A fresh look at antiarrhythmics
J. Thireau
Pharmacology & Therapeutics, 2011
View PDFchevron_right
Clinical Potential of Emerging Antiarrhythmic Agents
Giovanni Villani
Drugs in R & D, 1999
View PDFchevron_right
The Role of Antiarrhythmic Drug Therapy for the Prevention of Sudden Cardiac Death
Suneeta Mittal
Progress in Cardiovascular Diseases, 2008
View PDFchevron_right
Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE2, STRIDE2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE
MANSOOR NASIR
European Journal of Heart Failure, 2005
View PDFchevron_right
Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials
Mauro Gatti
View PDFchevron_right
Update on antiarrhythmic drug pharmacology
Christopher Huang
Journal of Cardiovascular Electrophysiology, 2020
View PDFchevron_right
What prevents cardioprotective drugs from reaching the market?
Fedor Simko
Expert Review of Clinical Pharmacology
View PDFchevron_right
Highlights of the 49 th Scientific Sessions of the American College of Cardiology
Andrew Civitello
2000
View PDFchevron_right
Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?
Francesca Palano , Lorenzo Semprini , Massimo Caprinozzi
ISRN Cardiology, 2014
View PDFchevron_right
Innovative approaches to anti-arrhythmic drug therapy
Stanley Nattel
Nature Reviews Drug Discovery, 2006
View PDFchevron_right
Antiarrhythmic drug therapy: what is certain and what is to come
Alessandro Capucci
European Heart Journal Supplements, 2003
View PDFchevron_right
Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy
David A Lathrop
Circulation Research, 2004
View PDFchevron_right
Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase
KRISHNA PRASAD K R
American Heart Journal, 2011
View PDFchevron_right
Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias
Frank Starmer
Circulation, 1990
View PDFchevron_right
Meeting Highlights : Highlights of the 49th Scientific Sessions of the American College of Cardiology
Andrew Civitello
Circulation, 2000
View PDFchevron_right
Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT
A. Yassin , Damien Cullington , Pierpaolo Pellicori , Huan Loh
European Journal of Heart Failure, 2009
View PDFchevron_right
Can Antiarrhythmic Drugs Survive Survival Trials?
John Camm
The American Journal of Cardiology, 1998
View PDFchevron_right
New developments in atrial antiarrhythmic drug therapy
Charles Antzelevitch
Nature Reviews Cardiology, 2010
View PDFchevron_right
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
Andrea Laslop
European heart journal. Acute cardiovascular care, 2016
View PDFchevron_right
Cardiovascular Paradigms: Time for Reappraisal (EC CARDIOLOGY Editorial)
Antonio Heitor Reis
2017
View PDFchevron_right
Choice and chance in drug therapy of cardiac arrhythmias: Technique versus drug-specific responses in evaluation of efficacy
balbir B singh
The American Journal of Cardiology, 1993
View PDFchevron_right
Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative
Michael K Pugsley
Journal of pharmacological and toxicological methods, 2017
View PDFchevron_right
Efficacy, safety and cost of new cardiovascular drugs: a survey
Vittorio Bertele'
European Journal of Clinical Pharmacology, 2003
View PDFchevron_right
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations
Masafumi Kitakaze
Basic Research in Cardiology, 2010
View PDFchevron_right
Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR
Hussien Hado
European Journal of Heart Failure, 2010
View PDFchevron_right
The use of antiarrhythmic agents in heart failure: Implications of CAST
Stephen Gottlieb
American Heart Journal, 1989
View PDFchevron_right
New Horizons in Cardioprotection
J. Vinten-johansen
Circulation, 2011
View PDFchevron_right
Prevention of Sudden Cardiac Death
Gabor Duray
Circulation Journal, 2005
View PDFchevron_right
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology
Marek Malik
Cardiovascular Research, 2000
View PDFchevron_right